Univariate and multivariate logistic regression analysis for predicting pregnancy failure after fertility-sparing hormonal treatment for early endometrial cancer
| Univariate analysis | Multivariate analysis | |||
| OR (95% CI) | P values | OR (95% CI) | P values | |
| Age | 1.05 (0.9 to 1.2) | 0.47 | 1.05 (0.8 to 1.3) | 0.69 |
| BMI | ||||
| Normal to over weight | 1 | |||
| Obesity | 1.12 (0.3 to 3.5) | 0.85 | ||
| Grade | ||||
| 1 | 1 | |||
| 2 | 4.75 (0.9 to 25.0) | 0.06 | 6.2 (1.0 to 38.9) | <0.05 |
| PCO in ultrasonography | 0.8 (0.2 to 2.7) | 0.72 | ||
| Operation history | 0.98 (0.3 to 3.0) | 0.97 | ||
| Medical history | 0 | 0.99 | ||
| Initial CA 125 | 0.97 (0.9 to 1.0) | 0.3 | ||
| Superficial myometrium invasion | 0.76 (0.1 to 4.2) | 0.75 | ||
| Endometrial mass size | ||||
| <1 cm | 1 | |||
| >1 cm | 0.8 (0.09 to 6.0) | 0.77 | ||
| Treatment time | ||||
| ≤9 months | 1 | |||
| >9 months | 0.83 (0.26 to 2.6) | 0.75 | ||
| Remission months | ||||
| ≤6 months | 1 | |||
| >6 months | 1.8 (0.5 to 5.6) | 0.31 | ||
| MPA dose | ||||
| 500 mg, once daily | 1 | |||
| 1000 mg, once daily | 1.5 (0.4 to 5.3) | 0.47 | ||
| Number of D&Cs | ||||
| ≤3 | ||||
| >3 | 1.6 (0.5 to 5.0) | 0.42 | ||
| Initial endometrium thickness | 0.9 (0.8 to 1.0) | 0.31 | ||
| ≤10 mm | ||||
| >10 mm | 0.31 (0.07 to 1.2) | 0.097 | 0.23 (0.4 to 1.0) | 0.06 |
| End of treatment endometrial thickness | ||||
| <4 mm | ||||
| ≥4 mm | 0.71 (0.2 to 2.2) | 0.57 | ||
BMI, kg/m2 (Korean Society for the Study of Obesity: normal BMI 18.5–23; overweight 23–25; obesity >25).
BMI, body mass index; CA, cancer antigen; D&C, dilatation and curettage; MPA, medroxyprogesterone acetate; PCO, polycystic ovary.